KRT8

(redirected from CK8)

KRT8

A gene on chromosome 12q13.13 that encodes a type-II cytokeratin that heteropolymerises to form intermediate filaments in epithelial cell cytoplasm. The KRT 8 typically dimerises with KRT 18 to form an intermediate filament in simple single-layered epithelial cells. KRT8  plays a role in maintaining cellular structural integrity, in signal
transduction and cell differentiation.

Molecular pathology
KRT8 mutations cause cryptogenic cirrhosis.
Mentioned in ?
References in periodicals archive ?
TCC are immunohistochemically reactive for CD10, AMACR (P504-S), CK8, CK18, and CK19 (3, 6).
5] The epithelial component of the tumour typically stains with a number of cytokeratin (CK) markers, namely AE1/AE3, CK8, CK7 and CK20.
3) Special techniques such as Ki-67 staining and immunohistochemistry studies for cytokeratin subtypes CK8, CK7, and CK19 might guide in pathologically differentiating SNUC from nasopharyngeal carcinoma and squamous cell carcinoma.
Samples were counterstained with Harris' hematoxylin (Biopur, Rosario, Argentina) for BrdU labeling or with Mayer's hematoxylin for CK8, p63, and RMCP-I detection, and mounted with permanent mounting medium (PMyR, Buenos Aires, Argentina).
2 antibody is specific for CK8 and, to a lesser extent, for the closely related CK7, but shows no reactivity with CK18.
We investigated the distortion effect of this modified aRNA amplification method on the relative mRNA abundance by comparing the expression of CK8, CK19, mammaglobin 1 (MGB1), mammaglobin 2 (MGB2), prolactin-inducible protein (PIP), EpCAM, PSA, and PSMA in RNA libraries obtained from tumor cell lines with and without amplification.
2 antibody has often been used in conjunction with a broad-spectrum anti-CK antibody, it has specificity against CK8, expressed in most (40%-100%), but not all, RCCs, but it lacks specificity for CK18, expressed in almost all RCCs.
Additionally, various low-molecular-weight cytokeratins (CKs) (eg, CK8, CK18, and CK19), and chromogranin A will be immunoreactive.
Whereas hypertrophic gene collagen [chi], platelet-derived growth factor [alpha], and reticulocalbin 3 have been identified in chondroid tumors, but not in chordomas, specific cytokeratins such as CK8, CK15, and CK19; periplakin; CD24; discoidin domain receptor 1; and brachyury are noticeably expressed in chordoma.
Similarly, cytokeratins (CK), mainly pancytokeratin, CK8, and CK18 are variably expressed.
Cytokeratin (CK) Expression in Various Carcinoma Types of the Sinonasal Tract and Nasopharynx (a) AE1/AE3 CK5/6 CK7 CK8 CK13 SCC + + (9/10) + (6/10) + (9/10) + (9/10) NKSCC + + (9/10) - + (9/10) + (9/10) SNUC + - + (3/6) + (6/6) - NPC + + (4/5) - + (4/5) + (4/5) CK14 CK19 SCC + (8/10) + (9/10) NKSCC + (8/10) + (9/10) SNUC - + (3/6) NPC - + (5/5) Abbreviations: NKSCC, nonkeratinizing squamous cell carcinoma; NPC, nasopharyngeal carcinoma, undifferentiated type; SCC, squamous cell carcinoma; SNUC, sinonasal undifferentiated carcinoma.
4-7) Among the cytokeratins, the reported percentage of expression in ES is as follows: CK8, 94%;CK14, 48%;and CK19, 72%, but rarely, CK7, 22%;CK20, 15%;or CK5/6, 30%, focal.